Montelukast Accord (Montelukast)

Montelukast Accord acts on the leukotriene pathway to control chronic respiratory and allergic conditions.

• Asthma: reduces bronchoconstriction and airway inflammation, improving control of persistent asthma.
• Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis.
• Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

• Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from binding and triggering bronchoconstriction, mucus secretion, and inflammatory cell recruitment in the airways, thereby reducing asthma and allergic symptoms.

Montelukast may cause a range of adverse reactions.

Common Side Effects

• Headache
• Abdominal pain
• Cough
• Sore throat
• Nausea
• Diarrhoea

Serious or Rare Side Effects

• Allergic reactions such as rash, angioedema or anaphylaxis
• Neuropsychiatric events including depression, anxiety or suicidal thoughts
• Elevated liver enzymes or hepatitis
• Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Eosinophilic pneumonia

When prescribing Montelukast Accord, consider the following safety points.

• Acute asthma attacks: do not use as rescue medication; provide a fast‑acting bronchodilator instead.
• Neuropsychiatric events: monitor patients for mood changes, depression or suicidal ideation.
• Hepatic impairment: use with caution; dose adjustment may be required.
• Known hypersensitivity: avoid in patients with documented allergy to Montelukast or any component of the tablet.
• Pregnancy and lactation: assess risk‑benefit, as limited data are available.
• Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

• Phenobarbital: enzyme induction may reduce Montelukast plasma concentrations and efficacy.
• Ketoconazole: strong CYP3A4 inhibition can increase Montelukast levels, raising risk of adverse effects.
• Other leukotriene pathway inhibitors (e.g., zileuton): additive effect may increase risk of liver toxicity.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: possible alteration of hormonal effectiveness.
• Theophylline: monitor plasma concentrations as Montelukast may affect metabolism.